baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

L&S Knock-Out Zealand Pharma A/S/ DE000LX4AG77 /

2024-10-11 8:15:52 AM	Chg.+0.10	Bid10:00:22 PM	Ask10:00:22 PM	Underlying	Strike price	Expiration date	Option type
2.68EUR	+3.88%	- Bid Size: -	- Ask Size: -	-	82.1532 EUR	2078-12-31	Call

GlobeNewswire 08-22 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

GlobeNewswire 08-15 Zealand Pharma Announces Financial Results for the First Half of 2024

GlobeNewswire 08-12 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial...

GlobeNewswire 07-29 Zealand Pharma Appoints Eric Cox as Chief Commercial Officer

GlobeNewswire 06-26 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary share...

GlobeNewswire 06-25 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900...

GlobeNewswire 06-25 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 90...

GlobeNewswire 06-20 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose ...

GlobeNewswire 06-07 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improveme...

GlobeNewswire 06-07 Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsenin...

GlobeNewswire 06-06 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial ...

GlobeNewswire 05-31 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...

GlobeNewswire 05-29 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

GlobeNewswire 05-23 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low ...

GlobeNewswire 05-16 Zealand Pharma Announces Financial Results for the First Quarter of 2024

GlobeNewswire 05-09 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...

GlobeNewswire 03-20 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...

GlobeNewswire 03-01 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference

GlobeNewswire 02-27 Zealand Pharma Announces Financial Results for the Full Year 2023

TeleTrader 02-26 Zealand Pharma soars 30% on positive weight-loss drug results

GlobeNewswire 02-26 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...

GlobeNewswire 02-26 Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...

GlobeNewswire 02-20 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financia...

GlobeNewswire 01-19 Zealand Pharma major shareholder announcement: J O Hambro Capital Management

GlobeNewswire 01-17 Zealand Pharma major shareholder announcement: J O Hambro Capital Management

L&S Knock-Out Zealand Pharma A/S/ DE000LX4AG77 /

If you wish to receive reply to your feedback, please provide your email address.